Intravenous bisphosphonate therapy in children wih osteogenesis imperfecta

Pediatrics

Volumn 111, Issue 3, 2003, Pages 573-578

  Falk, Marni J ^a,b   Heeger, Shauna ^a   Lynch, Katherine A ^a   DeCaro, Kathleen R ^b   Bohach, Deborah ^b   Gibson, Karen S ^b   Warman, Matthew L ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c NONE   (United States)

Author keywords

Bisphosphonate; Bone density; Osteogenesis imperfecta; Pamidronate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; PAMIDRONIC ACID;

ADOLESCENT; APPETITE DISORDER; ARTICLE; BONE DENSITY; BONE MINERAL; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FRACTURE; HUMAN; IRRITABILITY; LUMBAR SPINE; MALE; MOOD DISORDER; MYALGIA; OCCUPATIONAL THERAPY; OSTEOGENESIS IMPERFECTA; PHYSICAL ACTIVITY; PRIORITY JOURNAL; SCORING SYSTEM; TACHYCARDIA; TASTE DISORDER; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; AGE FACTORS; BONE DENSITY; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; DISABILITY EVALUATION; FEMALE; FRACTURES, BONE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; KNEE JOINT; LUMBAR VERTEBRAE; MALE; OCCUPATIONAL THERAPY; OSTEOGENESIS IMPERFECTA; TREATMENT OUTCOME;

EID: 0037342579     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.111.3.573     Document Type: Article

References (24)

1. Marini JC, Chernoff EJ. Osteogenesis imperfecta. In: Cassidy SB, Allanson JE, eds. Management of Genetic Syndromes. Philadelphia, PA: Wiley-Liss Inc; 2001:281-300
2. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16:101-116
3. Marini JC. Osteogenesis imperfecta: managing brittle bones [editorial]. N Engl J Med. 1998;339:986-987
4. Antoniazzi F, Bergoldo F, Mottes M, et al. Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis. J Pediatr. 1996;129:432-439
5. Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A. Intravenous pamidronate treatment in osteogenesis imperfecta. Eur J Pediatr. 1998;157:261-262
6. Åström E, Söderhäll S. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr. 1998;87:64-68
7. Åström E, Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child. 2002;86:356-364
8. Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, Van de Kamp JJP, Papapoulos SE. Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate). Eur J Pediatr. 1997;156:792-794
9. González E, Pavia C, Ros J, Villaronga M, Valls C, Escolá J. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab. 2001;14:529-533
10. Roldán E, Pasqualini T, Plantalech L. Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not strength. Report of two patients. J Pediatr Endocrinol Metab. 1999;12:555-559
11. Bembi B, Parma A, Bottega M, et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J Pediatr. 1997;131:622-625
12. Brumsen C, Hamdy N, Papapoulos SE. Long term effects of bisphosphonates on the growing skeleton: studies of young patients with severe osteoporosis. Medicine. 1997;76:266-283
13. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952
14. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab. 2000;85:1846-1850
15. Licata AA. Bisphosphonate therapy. Am J Med Sci. 1997;313:17-22
16. Njeh CF, Jergas M, Genant HK. Bone density and imaging of osteoporosis. In: Degroot LJ, Jameson LJ, eds. Endocrinology. 4th ed. New York, NY: WB Sanders Co; 2001:1187-1190
17. Haley SM, Coster WJ, Ludlow LH, Haltiwanger JT, Andrellos PJ. Pediatric Evaluation of Disability Inventory (PEDI), Version 1.0: Development, Standardization, and Administration Manual. Boston, MA: New England Medical Center Hospitals Inc, and PEDI Research Group; 1992
18. Zanchetta JR, Plotkin H, Alvarez Filgueira ML. Bone mass in children: normative values for the 2-20-year-old population. Bone. 1995;16:393S-399S
19. Davie MWJ, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child. 1994;70:331-334
20. Lund AM, Mølgaard C, Müller J, Skovby F. Bone mineral content and collagen defects in osteogenesis imperfecta. Acta Pediatr. 1999;88:1083-1088
21. Cepollaro C, Gonnelli S, Pondrelli C, et al. Osteogenesis imperfecta: bone turnover, bone density, and ultrasound parameters. Calcif Tissue Int. 1999;65:129-132
22. Landman JO, Hamdy NAT, Pauwels EKJ, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after dicontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab. 1995;80:3465-3468
23. Gamble JG, Rinsky LA, Strudwick J, Bleck EE. Non-union of fractures in children who have osteogenesis imperfecta. J Bone Joint Surg (Am). 1988;70-A:439-443
24. Zacharin M, Bateman J. Pamidronate treamlent of osteogenesis imperfecta - lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response. J Pediatr Endocrinol Metab. 2002;15:163-174